Author: Pelaia, Corrado; Calabrese, Cecilia; Garofalo, Eugenio; Bruni, Andrea; Vatrella, Alessandro; Pelaia, Girolamo
Title: Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence Cord-id: boos66m3 Document date: 2021_3_17
ID: boos66m3
Snippet: Among patients suffering from coronavirus disease 2019 (COVID-19) syndrome, one of the worst possible scenarios is represented by the critical lung damage caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-induced cytokine storm, responsible for a potentially very dangerous hyperinflammatory condition. Within such a context, interleukin-6 (IL-6) plays a key pathogenic role, thus being a suitable therapeutic target. Indeed, the IL-6-receptor antagonist tocilizumab, already
Document: Among patients suffering from coronavirus disease 2019 (COVID-19) syndrome, one of the worst possible scenarios is represented by the critical lung damage caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-induced cytokine storm, responsible for a potentially very dangerous hyperinflammatory condition. Within such a context, interleukin-6 (IL-6) plays a key pathogenic role, thus being a suitable therapeutic target. Indeed, the IL-6-receptor antagonist tocilizumab, already approved for treatment of refractory rheumatoid arthritis, is often used to treat patients with severe COVID-19 symptoms and lung involvement. Therefore, the aim of this review article is to focus on the rationale of tocilizumab utilization in the SARS-CoV-2-triggered cytokine storm, as well as to discuss current evidence and future perspectives, especially with regard to ongoing trials referring to the evaluation of tocilizumab’s therapeutic effects in patients with life-threatening SARS-CoV-2 infection.
Search related documents:
Co phrase search for related documents- abdominal pain and acute ards respiratory distress syndrome: 1, 2, 3, 4
- abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- abdominal pain and adjuvant therapy: 1
- abdominal pain and liver damage: 1, 2, 3, 4, 5, 6, 7, 8
- abdominal pain and low mortality: 1, 2
- abdominal pain and low number: 1
- abdominal pain and lung damage: 1
- abdominal pain and lung failure: 1, 2
- abdominal pain and lung tissue: 1, 2
- abdominal pain and macrophage inflammatory: 1
- aberrant activation lymphopenia and activation lymphopenia: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date